Heart failure & cardiomyopathies
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
Authors' conclusion
Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.
Study context
- Population
- Heart failure (HF) patients grouped by recency of HF hospitalization (none, <3 months, 3–6 months, 6–12 months, >12 months)
- Participants
- 9,718 patients
- Comparison
- Empagliflozin vs placebo, by recency of prior HF hospitalization
- Primary endpoint
- Composite of:
- Time to first HF hospitalization
- CV death
- Follow-up
- Median 21 months
Methodological detailssubgroup analysis by recency of HF hospitalization, pooled EMPEROR-Reduced and EMPEROR-Preserved
- Subgroup analysis by recency of HF hospitalization
- Pooled EMPEROR-Reduced and EMPEROR-Preserved
Primary result
As reported in the abstract
HF hospitalization or CV death, by recency of HF hospitalization
- Placebo event rate, hospitalized <3 months (per 100 person-years)
- 26.7
- Placebo event rate, hospitalized 3-6 months (per 100 person-years)
- 18.1
- Placebo event rate, hospitalized 6-12 months (per 100 person-years)
- 13.7
- Placebo event rate, hospitalized >12 months (per 100 person-years)
- 2.8
- Relative risk reduction with empagliflozin similar across HF hospitalization categories
- P interaction = 0.67
- Absolute risk reduction, hospitalized <3 months (events per 100 person-years)
- −6.9
- Absolute risk reduction, hospitalized 3-6 months (events per 100 person-years)
- −5.5
- Absolute risk reduction, hospitalized 6-12 months (events per 100 person-years)
- −0.8
- Absolute risk reduction, hospitalized >12 months (events per 100 person-years)
- −0.6
- Absolute risk reduction, no prior HF hospitalization (events per 100 person-years)
- −2.4
- No statistical heterogeneity of absolute risk reduction
- P interaction = 0.64
Safety
- Empagliflozin safe irrespective of HF hospitalization recency
Original publication
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis. JACC Heart Fail. Published 20 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →